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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the efficacy of vitamin C for treating AF, and for the secondary prevention of AF.
B A C K G R O U N D
Description of the condition
Atrial fibrillation (AF) is the most common sustained arrhythmia
encountered in clinical practice and contributes substantially to
cardiac morbidity and mortality (Lip 2012; Page 2004). Prevalence
of AF increases with age from about 0.1% among adults under
55 years to about 10% in people aged over 80 years (Go 2001;
Kirchof 2012).
AF is characterized by rapid and irregular activation of the atrium
at a rate of > 300 pulses of the atrium muscular wall per minute
(Lip 2012). This is much higher than the rate when the heart is in
normal sinus rhythm (SR). In AF the ventricular rate is determined
by the interaction between atrial rate and the filtering function of
the atrioventricular node; and the ventricular rate may be about
150 beats per minute (bpm).
AF can cause palpitations, dyspnea, fatigue, light-headedness and
syncope (brief loss of consciousness, or ’fainting’) (Page 2004).
The more severe consequences of AF are thromboemboli (blood
clots which form in the blood vessels then circulate to other areas
of the body) and congestive heart failure (HF). AF may lead to
stasis (stagnation) of blood in the atria and clot formation, which
may further lead to thromboemboli. Owing to this, AF increases
the risk of stroke by five fold (Kannel 1998; Kirchof 2012). AF
may also lead to overload on the heart and thereby to HF. Thus,
AF is both a cause for, and a result of HF (Wang 2003).
There are over 30 causes for AF, which can be divided into cardio-
vascular and non-cardiovascular causes (Iqbal 2005). Due to the
high frequency in community, hypertension is the most common
risk factor for AF and explains over 10% of cases (Kannel 1998;
Kirchof 2012). ’Lone AF’ is a term used to describe cases who have
no identifiable causes, thus ’lone AF’ is a diagnosis based on exclu-
sions (Kozlowski 2009). A further approach to classifying AF is by
temporal basis to paroxysmal (self terminating), persistent (lasts >
7 days or requires cardioversion) and permanent (Page 2004).
AF can be triggered by various acute stressful conditions. About
30% of patients in cardiac operations get AF (Hogue 2005),
whereas only about 3% of patients in noncardiac operations get
AF (Bhave 2012). Nevertheless, although AF after cardiac surgery
is associated with a longer stay in hospital, it is not clear whether
the long stay is caused by AF or whether both of them are caused
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by other factors which differ between those patients who get AF
and those who do not get AF (Levy 2004). Heavy exercise may
also increase the risk of AF (Abdulla 2009; Turagam 2012).
Although AF is associated with increased morbidity and mortal-
ity, arrhythmia suppression is not necessarily a good surrogate for
clinical events of importance. Clinical events such as thromboem-
bolism, new or worsening HF and death should be preferred as
primary outcomes in studies on AF treatment (Wyse 2004).
Description of the intervention
Vitamin C was identified in the search for the substance which,
when deficient in the body, leads to scurvy (Carpenter 1986). This
history led to the assumption that the sole physiological function
of vitamin C is to prevent and treat scurvy. Therefore, it is often
assumed that higher doses of vitamin C cannot be beneficial in
a person who does not suffer from scurvy. Due to this history,
assessing the role of vitamin C on diseases and conditions other
than scurvy is not just an empirical question but also a conceptual
issue.
Vitamin C is an antioxidant and therefore the effects of supple-
mentation might occur or might be most pronounced under con-
ditions when there is increased oxidative stress in the body.
Aging leads to an increase in oxidative stress (Toroser 2007; Dai
2009). Therefore, vitamin C might have a different influence on
the elderly compared with middle-aged and young people. In a
large-scale cancer prevention trial amongst smokers, vitamin E
decreased mortality in the oldest males only if they had high dietary
vitamin C intake (Hemilä 2009; Hemilä 2011). This modification
was specific to vitamin C and was not explained by other substances
in fruit, vegetables or berries (Hemilä 2009). In a meta-analysis of
29 trials, vitamin C was found to reduce blood pressure (Juraschek
2012), but the studies were short and the practical importance of
this effect is not clear.
Exercise causes oxidative stress (Powers 2011) which is prevented
by vitamin C (Silvestro 2002). Thus, vitamin C might affect peo-
ple who endure heavy physical stress. In five trials with participants
who had short-term heavy physical stress, vitamin C halved the in-
cidence of common cold symptoms, and in three trials with partic-
ipants who suffered from exercise-induced bronchoconstriction,
vitamin C halved the FEV1 decline caused by exercise (Hemilä
2014).
Infections cause oxidative stress because activated leukocytes re-
lease reactive oxygen and nitrogen species (Akaike 2001; Galley
1996); therefore, vitamin C levels are decreased in various infec-
tions (Hemilä 2006). Over two dozen trials have shown that vita-
min C shortens the duration of colds (Hemilä 2013a) and two tri-
als reported therapeutic benefit for pneumonia patients (Hemilä
2013b).
In randomized trials with critically ill intensive care unit (ICU)
patients, vitamin C (Tanaka 2000) and the combination of vita-
mins C and E (Nathens 2002) significantly decreased the length
of mechanical ventilation. In a case-control study, ICU patients
who were given vitamins C and E and selenium had shorter ICU
stays and lower mortality rates (Collier 2008).
Low vitamin C intakes are not just of historical interest. Cases
of scurvy are being reported even nowadays (Holley 2011; Smith
2011) and a survey in a French geriatric acute care ward estimated
that about 10% of patients had clinical symptoms of scurvy (
Raynaud-Simon 2010). In the UK, 25% of men and 16% of
women from low-income populations had vitamin C deficiency
(< 11 µmol/L) (Mosdøl 2008), and in the USA, 7% of healthy
middle-class participants of a survey had vitamin C deficiency
(Schleicher 2009). Thus, if low intakes of vitamin C might provide
less protection against oxidative stress and thereby might increase
the risk of AF, this issue could be important in substantial segments
of Western countries.
Approximately 10 mg/day of vitamin C prevents scurvy but the
safe dose range extends to grams per day (Hemilä 2006; IOM
2000). In the US nutritional recommendations, the ’tolerable up-
per intake level’ is stated to be 2 g/day for adults. However, the ba-
sis for this upper limit is the appearance of diarrhoea (IOM 2000)
which is a trivial adverse effect that disappears quickly with a re-
duction in intake. In a pharmacokinetic study, participants were
administered up to 100 grams of vitamin C intravenously within
a few hours without any reported adverse effects, indicating the
safety of such a very large dose in healthy people (Padayatty 2004).
Two large-scale trials with 8171 female health professionals and
14,641 male physicians found no adverse effects of 0.5 g/day of
vitamin C when administered for 8 to 9 years indicating long term
safety of such a dosage level (Cook 2007; Sesso 2008).
Finally, vitamin C is cheap and costs pennies per gram. Therefore,
its effects are interesting even if the size of the effect might not be
very large.
How the intervention might work
AF is associated with oxidative stress (Korantzopoulos 2007), and
it seems that the cause-effect relation works in both directions.
There is much evidence from animal studies that tachycardia (rapid
heart rate) leads to oxidative stress. In the hearts of dogs artificially
kept at rapid ventricular pacing at 240 bpm, the production of
superoxide (Ide 1999) and hydroxyl radical (Ide 2000) is increased.
In addition, in tachycardic dogs the atrial content of nitrotyrosine
was increased and vitamin C level was decreased (Carnes 2001). In
rabbits, rapid cardiac pacing increased myocardial oxidative stress
as evidenced by the increase in the ratio of oxidized to reduced
glutathione and increased level of oxidized mitochondrial DNA
(Shite 2001). In pig hearts, experimentally initiated AF increased
superoxide production (Dudley 2005). Thus, high cardiac rate
appears to cause oxidative stress.
Oxidative stress may, in turn, increase the susceptibility of the
heart to tachycardia. In the isolated hearts of aged rats and middle-
aged rabbits, hydrogen peroxide exposure increased susceptibility
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to ventricular tachycardia, whereas in young rats and rabbits it did
not cause tachycardia (Morita 2009). Oxidative stress is elevated in
several conditions which increase AF risk, such as age (Dai 2009),
coronary artery bypass graft (CABG) surgery (De Vecchi 1998),
hypertension (Montezano 2012) and exercise (Powers 2011), and
could thus play a role in the emergence of AF.
In humans with AF, oxidative stress was indicated by the increase in
the ratio of oxidized to reduced glutathione (Neuman 2007), and
decrease in myofibrillar creatine kinase (MM-CK) activity which
was inactivated by nitration (Mihm 2001). In the atria of human
AF patients the expression of five genes related to the generation
of oxidants was increased whereas the expression of two genes re-
lated to antioxidants was decreased (Kim 2003). A major source
of superoxide in the heart is NADPH oxidase (Montezano 2012),
the activity of which was increased in the right atrial appendage
of AF patients compared with patients who were in sinus rhythm
(SR) (Kim 2005). Although these correlations in human observa-
tional studies indicate association between oxidative stress and AF,
the direction of cause is undetermined. Nevertheless, in a further
study, high atrial NADPH oxidase level predicted postoperative
AF (Kim 2008), which implies that oxidative stress preceded AF.
Several ion channels expressed in the atria are sensitive to the
redox state and, therefore, oxidative stress and antioxidants might
influence the electrophysiology of atria (Van Wagoner 2008).
Superoxide reacts with nitric oxide to produce peroxynitrite, a
strong oxidant. Vitamin C reacts with superoxide (Nishikimi
1975) and with radicals produced by peroxynitrite (Kirsch 2000)
and it might thereby influence AF. In tachycardic dogs, vitamin
C prevented the increase in nitrotyrosine levels (Carnes 2001).
Another study with tachycardic dogs found that the antioxidant
N-acetylcysteine (NAC) enhanced recovery of contractile function
after a rapid pacing period (Gare 2002).
In a randomized trial on patients undergoing CABG or valve
surgery (or both), administration of NAC decreased the incidence
of postoperative AF (Ozaydin 2008). The combination of vita-
mins C and E with omega-3 fatty acid decreased postoperative AF
significantly in two studies (Rodrigo 2012; Rodrigo 2013), and
nonsignificantly in a third study (Castillo 2011). The combination
of vitamins C and E with allopurinol decreased the occurrence
of postoperative arrhythmia in CABG patients (Sisto 1995). In a
case-control study, the incidence of postoperative AF was lower
in CABG patients administered vitamin C (Carnes 2001). Thus,
antioxidants might have an effect on the risk of postoperative AF.
It is possible that vitamin C has different effects on different forms
of AF. For example, it seems probable that the effect of vitamin C
might be greater on paroxysmal than on permanent AF. It seems
also probable that vitamin C has different effects depending on
the etiology of AF.
Why it is important to do this review
AF is the most common of the serious cardiac rhythm disturbances
and vitamin C is a safe and inexpensive essential nutrient. The pos-
sibility that vitamin C might have preventive or therapeutic effects
against AF, even in restricted population groups, is worth exam-
ination. A previous meta-analysis focused on the antiarrhythmic
effects of antioxidants following cardiac surgery (Harling 2011),
but further studies on vitamin C and AF have been published since
then. The benefit of Cochrane reviews is that they can be kept up
to date when new trials are published. In addition, the Harling
2011 review was restricted to studies related to cardiac surgery. No
previous Cochrane review has examined the topic of this protocol.
O B J E C T I V E S
To assess the efficacy of vitamin C for treating AF, and for the
secondary prevention of AF.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomized controlled trials.
For secondary prevention trials, the use of placebo in the control
group will not be required as it seems unlikely that being aware of
taking or not taking vitamin C would influence the occurrence of
AF. A recent meta-analysis of trials comparing a placebo group with
a no treatment group found evidence that the placebo effect on
binary outcomes is small at best (Hrobjartsson 2010). Thus, there
is no empirical evidence indicating that the placebo effect might
substantially influence the type of outcome as the occurrence of
AF.
For treatment trials on the incidence of embolic events and return
to SR, the use of placebo in the control group will not be required
given the above reasoning. In treatment trials reporting on the
duration of hospitalization and the incidence of HF associated
with AF, we will restrict these to placebo controlled trials, since
it is possible that the lack of placebo might bias observations on
such outcomes.
We will include trials reported as full-text or abstract, and we will
include trials that are unpublished if we get the data. We will
study the influence of methodologically less satisfactory trials by
sensitivity analysis.
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Types of participants
Secondary prevention
We will include trials with people of any age who do not have AF
at the baseline, but who have had AF or who have a particularly
high risk of AF.
Treatment
We will include trials with people of any age who have AF. We will
include studies with all types of AF.
Types of interventions
The intervention considered is oral or intravenous administration
of vitamin C (ascorbic acid or its salts). We do not set a lower
limit to the dose of vitamin C or to the duration of vitamin C
supplementation.
The primary focus in this review is on the comparison of vitamin
C against a control group with or without placebo, so that all co-
interventions are equal in the trial arms. Nevertheless, trials com-
paring vitamin C against standard AF drugs will also be included.
Types of outcome measures
Primary outcomes
1. Secondary prevention trials: incidence of AF.
2. Treatment trials: incidence of embolic events.
3. Treatment trials: incidence of new HF and worsening of
existing HF.
4. All cause mortality.
5. Adverse effects.
Secondary outcomes
1. Treatment trials: return to SR.
If there are data on the effect of vitamin C on quality of life and
economic costs, they will be described.
Adverse events reported in the trials will be collected, but it is
unlikely that the trials on AF are informative on this issue, given
the findings in previous large-scale trials with follow-ups of sev-
eral years duration (Cook 2007; Sesso 2008) and in short studies
with particularly high vitamin C doses (e.g. Padayatty 2004) and
other extensive literature on vitamin C safety (Hemilä 2006; IOM
2000).
Search methods for identification of studies
Electronic searches
We will identify trials through systematic searches of the following
bibliographic databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL) in The Cochrane Library, latest issue;
• MEDLINE (Ovid);
• EMBASE (Ovid).
The search strategy for MEDLINE (Ovid) (Appendix 1) will be
adapted for use in the other databases. We will not use filters, but
we will hand pick trials fulfilling our inclusion criteria.
We will also conduct a search of ClinicalTrials.gov (
www.ClinicalTrials.gov) and the WHO International Clinical Tri-
als Registry Platform (ICTRP) Search Portal (http://apps.who.int/
trialsearch/).
We will search all databases from their inception to the present,
and we will impose no restriction on the language of publication.
We will use the Web of Science ’cited reference search’ to identify
papers that have cited the included trials as a way to check that no
relevant studies are missed, e.g. because of miscoding of publica-
tions.
Searching other resources
We will check reference lists of all included trials and relevant
review articles for additional references. We will contact authors of
published studies to ask if they know of ongoing or unpublished
trials.
Data collection and analysis
Selection of studies
Two authors (HH, TS) will independently screen titles and ab-
stracts for inclusion of the potential trials identified in the litera-
ture search, and will code them as ’retrieve’ (eligible or potentially
eligible) or ’do not retrieve’. If there are disagreements between the
two authors at this stage, the full paper will be retrieved. We will
retrieve the full-text trial reports and abstracts, and two authors
(HH, TS) will independently screen the reports and identify tri-
als for inclusion, and record reasons for exclusion of the ineligi-
ble studies. Similarly, if we find potentially relevant unpublished
results, the two authors will independently consider their inclu-
sion. We will resolve any disagreements through discussion. We
will identify duplicate reports and collate multiple reports of the
same trial so that the unit of interest is the trial. We will record the
selection process in sufficient detail to complete a PRISMA flow
diagram and ’Characteristics of excluded studies’ table.
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Data extraction and management
We will use a data collection form for trial characteristics and out-
come data which has been piloted on at least one trial in the review.
One author (HH) will extract study characteristics from included
trials and another author (TS) will confirm the extraction. We will
extract the following study characteristics.
1. Methods: study design, total duration of the trial, details of
any ’run in’ period, trial setting, withdrawals, and date of trial.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, inclusion criteria, and exclusion
criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes of the trial,
and time points reported.
5. Potential conflicts of interest: funding for trial and other
potential conflicts of interest of trial authors.
6. Additional notes.
Two authors (HH, TS) will independently extract outcome data
from included trials. If an included trial does not report data in
such a way that it can be included in statistical analyses, the results
will be narratively described in the Results section. We will resolve
disagreements by discussion. One author (HH) will transfer data
into Review Manager 5 (RevMan 2012). The second author (TS)
will check the entered results against the original trial reports. We
will contact authors to ask for more data when needed. If data are
not reported in a way that they can be included in the statistical
analyses, we will try to contact the authors to obtain the data in a
different form. The outcome of the contacts will be reported.
Assessment of risk of bias in included studies
Two authors (HH, TS) will independently assess risk of bias for
each trial using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We will resolve
any disagreements by discussion. We will assess the risk of bias
according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We will grade each potential source of bias as high, low or unclear
and provide a quote from the trial report together with a justifi-
cation for our judgment in the ’Risk of bias’ table. We will sum-
marize the risk of bias judgements across different trials for each
of the domains listed. Where information on risk of bias relates to
unpublished data or correspondence with a trialist, we will note
this in the ’Risk of bias’ table.
When considering intervention effects, we will take into account
the risk of bias for the trials which contribute to that outcome.
Measures of treatment effect
We will analyze dichotomous data as risk ratios (RR) with 95%
confidence intervals (CI) and continuous data as percentage effects
with the 95% CI. We will present the results in forest plots with
a consistent direction so that left from the control level means
benefit of intervention.
If an included trial does not report data in such a way that it can be
presented in a forest plot, the results will be narratively described
in the Results section.
Where multiple trial arms are reported in a single trial, we will
include only the relevant arms. If several arms are relevant, we will
divide the control group between the intervention arms evenly so
that the control participants are not double counted.
If only a few positive cases are observed for binary outcomes, the
mid-P value will be used to calculate the P values for the differences
between the treatment groups (Hemilä 2006; Lydersen 2009).
We will analyze participants in the groups in which they were
allocated. We will not impute outcome values for participants lost
to follow-up.
We will use two-tailed P values in this review.
Dealing with missing data
We will contact investigators to verify key study characteristics and
obtain missing outcome data when necessary (e.g. when a trial is
identified as abstract only). If we do not get relevant data, we will
explore the impact of such trials by a sensitivity analysis.
Assessment of heterogeneity
We will use the Chi2 test and the I2 statistic to assess statistical
heterogeneity among the trials in each meta-analysis (Higgins
2003). A value of I2 greater than about 70% indicates a high level
of heterogeneity. If we identify substantial statistical heterogeneity
we will report it and explore possible causes by subgroup analyses.
Assessment of reporting biases
We will construct and report funnel plots for the meta-analyses,
although they have been criticized as a tool for assessing whether
there is publication bias or not (Ioannidis 2007; Lau 2006; Sterne
2011; Terrin 2005). We follow the instructions of the Cochrane
Handbook for Systematic Reviews of Interventions: “Results from
tests for funnel plot asymmetry should be interpreted cautiously.
When there is evidence of small-study effects, publication bias
should be considered as only one of a number of possible expla-
nations. In these circumstances, review authors should attempt
to understand the source of the small-study effects, and consider
their implications in sensitivity analyses.” (Higgins 2011).
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We will also narratively consider the possibility of publication bias
in the Discussion section.
Data synthesis
If a group of trials is clinically sufficiently uniform in settings and
outcome definitions, and there is no substantial statistical hetero-
geneity between the results, we will pool the data using the fixed-
effect model. If the trials are heterogeneous, either statistically or
clinically, we will not pool them. Nevertheless, even if heterogene-
ity prevents pooling of a group of studies, the total evidence for
the difference between the vitamin C and control groups can be
tested by the combined P value (Fisher 1948).
Subgroup analysis and investigation of heterogeneity
We plan to present different conditions of AF separately as sub-
groups, such as AF related to cardiovascular surgery, recurrent AF
after cardioversion, etc. If there are suitable data available, we are
interested in the potential role of age, sex, vitamin C status (im-
portant, but rarely reported), and dosage of vitamin C as subgroup
variables. If we present subgroups, we plan to test subgroup inter-
actions in Review Manager (RevMan 2012).
Sensitivity analysis
We will carry out sensitivity analyses by only including trials with
a low risk of bias in all of the following items: random sequence
generation, allocation concealment, blinding of participants, per-
sonnel and outcome assessment, and incomplete outcome data.
A C K N O W L E D G E M E N T S
The background and methods section of this protocol is based on
the standard template used by Cochrane Heart Group.
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